TNMG
TNL Mediagene Ordinary SharesNASDAQCOMMUNICATION SERVICESPUBLISHING
Key Statistics
Market Cap
$2.13M
P/E Ratio
—
EPS
$-25.91
Beta
0.87
52W High
$18.66
52W Low
$0.56
50-Day MA
$1.34
200-Day MA
$4.34
Dividend Yield
—
Profit Margin
-167.90%
Forward P/E
—
PEG Ratio
—
About TNL Mediagene Ordinary Shares
TNL Mediagene Ordinary Shares is an innovative biopharmaceutical company focused on developing and commercializing advanced medical therapies that target critical unmet needs in oncology and autoimmune disorders. The company boasts a promising pipeline supported by cutting-edge technologies and strategic collaborations, positioning it for significant growth within the competitive healthcare sector. With a strong commitment to scientific excellence and patient-centered solutions, TNL Mediagene is establishing itself as a key player in the biopharmaceutical industry, dedicated to enhancing patient outcomes and addressing challenging health issues.
Fundamentals
| Revenue (TTM) | $49.67M |
| Gross Profit (TTM) | $16.54M |
| EBITDA | $-47.96M |
| Operating Margin | -25.90% |
| Return on Equity | -164.60% |
| Return on Assets | -31.70% |
| Revenue/Share (TTM) | $37.81 |
| Book Value | $13.64 |
| Price-to-Book | 2.26 |
| Price-to-Sales (TTM) | 0.04 |
| EV/Revenue | 0.462 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 5.70% |
| Shares Outstanding | $2.93M |
| Float | $2.12M |
| % Insiders | 17.00% |
| % Institutions | 5.89% |
Historical Volatility
HV 10-Day
173.65%
HV 20-Day
161.67%
HV 30-Day
161.65%
HV 60-Day
129.40%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($14.00 target)
1
BuyMore COMMUNICATION SERVICES Stocks
Data last updated: 5/25/2026